Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$9.00 USD
-0.24 (-2.60%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $9.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Travere Therapeutics, Inc. [TVTX]
Reports for Purchase
Showing records 1 - 20 ( 132 total )
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Recap: Significant FILSPARI Growth and Momentum Bodes Well for 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FILSPARI Approved For IgAN in Europe As Expected; First Market Launch in Europe Expected in 2H24; Increasing PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
sNDA Submitted For Full Approval of FILSPARI For IgAN; Approval in Europe Expected in 2Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap: Sparsentan Receives Positive CHMP Opinion; sNDA Submission for Full U.S. Approval in 1Q24; Trim PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Flipping Forward: 4Q23 Report As Anticipated, While Filspari Launch Progresses
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NNARR Below Buyside Expects; ARR Guided Down; Is FY25E Guide at Risk?
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Travere Signs Agreement For Sparsentan in Asia; IgAN Registrational Study in Japan to Begin in 2Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary 4Q FILSPARI Sales Exceed Our Estimates; Kicking Off 2024 With Two Regulatory Decisions in 1Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Drug Prices for the New Year; We Highlight Three Recent Price Changes in Our Coverage Universe
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Filspari Continues To Make Progress As TVTX Preannounces Beat
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal Phase 3 HARMONY Study of Pegtibatinase to Support First Potential Disease-Modifying Therapy For HCU; PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
sNDA Filing Planned in 1Q24 For FILSPARI''s Full Approval in IgAN; Reorganization Extends Cash Runway to 2028; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E